It is well known that traditional drug product optimization processes take significant time to complete. Great emphasis is placed on laboratory and preclinical assessments to identify human formulations [why?]. This non-optimal working model is necessitated by the multiple disciplines required to develop, manufacture, and test new formulations.
Quotient Sciences’ integrated development platform, Translational Pharmaceutics®, is a powerful solution to address the challenges of drug product optimization. First applied in 2008, it uses clinical data to improve decision-making and halve development timelines. This approach has been successfully applied to over 250 drug product optimization programs, delivering significant benefits in solubility enhancement and modified release development activities.
In a recent example [briefly describe what we did / how we applied it to a customer program].
In this video, watch Aruna Railkar, Senior Drug Development Consultant, speak on this topic at the 2024 Controlled & Modified Drug Release Summit in New Jersey.
Want to discuss your next program and how we might be able to help? Contact us today.